Author Topic: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc  (Read 263630 times)

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc
« Reply #1600 on: January 14, 2022, 03:53:41 PM »
Health departments in several states confirmed to The Epoch Times that they are looking into a steep surge in the mortality rate for people aged 18 to 49 in 2021—a majority of which are not linked to COVID-19. Deaths among people aged 18 to 49 increased more than 40 percent in the 12 months ending October 2021 compared to the same period in 2018–2019, before the pandemic
https://www.theepochtimes.com/several-states-examine-2021-mortality-surge-in-americans-aged-18-49_4213438.html?utm_source=partner&utm_campaign=gp
----------------------------------------------

I think this is fentanyl.  Still it's pandemic related if it came out of mandates and lockdowns.

I bet many are adverse reactions to the ClotShot.



Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile
WSJ: Long Live Super Immunity
« Reply #1601 on: January 18, 2022, 01:57:39 AM »
Herd Immunity Is Over—Long Live Superimmunity
The Omicron wave will leave most people with potent and durable protection against Covid.
By Allysia Finley
Follow
Jan. 17, 2022 5:25 pm ET


Forget about herd immunity. Covid-19 vaccines and prior infection don’t provide lasting protection against infection and transmission, especially with the Omicron variant. That makes it impossible for enough of the population to become immune to stop the virus from spreading.

But don’t despair. Omicron will give much of the population what some scientists call “superimmunity”—stronger protection against new variants and even future coronaviruses. Normal life will be possible even as the virus continues to spread and mutate. Superimmunity won’t necessarily stop people from being infected or transmitting the virus. But most people who get infected, even with a more virulent variant, will experience mild or no symptoms.


To understand why, consider how the immune system works. Two types of white blood cells, T- and B-cells, tag-team to vanquish invading pathogens. T-cells act as sentinels that circulate in the lymph nodes and bloodstream. When they spot an invader, they kick into action. One type of T-cell destroys infected cells. Another signals B-cells, the immune system’s force multipliers, to proliferate and secrete antibodies that neutralize the pathogen. Antibodies target proteins on the pathogen known as antigens.

Once the army of white blood cells and their antibody foot soldiers have defeated the virus, most die off. But some white blood cells that remember the pathogen persist and hone their combat skills. These so-called memory T-cells continue to reside in the bone marrow, lymph nodes and other tissues, ready to mobilize the immune system if they encounter the intruder again.


Meantime, memory B-cells go to boot camp in the lymph nodes, where they get into better fighting shape should the invader return. Memory B-cells train to produce antibodies that can block new variants. When and if the virus reappears, they can more rapidly reproduce and produce more-potent antibodies.

Vaccines emulate natural infection by training the immune system with a pseudo-virus or antigen—in the case of Covid-19, the spike on the surface of the virus that it uses to bind to human cells. Antibodies produced after vaccination tend to decline more rapidly than after infection, perhaps because the virus particles persist longer in the body than the vaccine-simulated antigens.

With both infection and vaccination, the immune system gets quicker, stronger and smarter after being exposed to a new challenge. Researchers have found that people who were infected by Covid-19 and later vaccinated crank out higher levels and a broader array of antibodies that last longer than do people who have only been vaccinated.


Similarly, a study last month by the Oregon Health and Science University found that vaccinated people who experienced breakthrough infections produced higher levels of antibodies that were up to 1,000% more effective than those generated two weeks after a second dose of the Pfizer vaccine. The researchers described this as superimmunity.

“I think this speaks to an eventual end game,” said co-author Marcel Curlin. “It doesn’t mean we’re at the end of the pandemic, but it points to where we’re likely to land: Once you’re vaccinated and then exposed to the virus, you’re probably going to be reasonably well-protected from future variants.” Dr. Curlin added: “Our study implies that the long-term outcome is going to be a tapering off of the severity of the worldwide epidemic.”

A study last month from South Africa found that people who were infected with Omicron produced antibodies that were more than four times better at neutralizing the Delta variant. Booster vaccines also improve the immune response by giving B-cells more time to mature—one reason antibodies after three Pfizer shots are capable in lab experiments of neutralizing Omicron while those after two aren’t.

But boosters train the immune system against the same target. Omicron’s myriad mutations create a bigger challenge for the B- and T-cells, and thereby strengthen the immune response. To use an analogy, if you train at doing push-ups, you’ll get stronger—but not as strong as if you also did pull-ups.

Infection also strengthens the T-cell response. T-cells from vaccinated people have been found to retain 70% to 80% of their efficacy against the Omicron variant spike protein. This has helped prevent more severe illness, even though vaccine antibodies are less effective against Omicron.

But infection trains T-cells to recognize virus proteins that also are less likely to mutate than the spike. Some of these proteins share similarities with the original SARS virus as well as four coronaviruses that can cause the common cold. SARS survivors have been found to have memory T-cells 17 years after infection that also recognized parts of the Covid-19 virus. A new study from the U.K.’s Imperial College found that people with pre-existing T-cells to non-spike proteins in common-cold coronaviruses were less likely to get infected with Covid-19.


All of this suggests that infection with Omicron is likely to stimulate potent and durable protection against Covid-19—and potentially other coronaviruses—even if it mutates to become more virulent. As Omicron rapidly spreads, people who have been vaccinated or previously infected will develop superimmunity. Covid-19 will become a virus that causes cold- and sometimes flulike symptoms—annoying but rarely deadly or disruptive.

One caveat is that older people generate weaker T-cell responses and memories to infections and vaccines. They’re likely to need annual booster shots. Omicron will end the pandemic by making Covid-19 endemic.

Ms. Finley is a member of the Journal’s editorial board.



ccp

  • Power User
  • ***
  • Posts: 18543
    • View Profile
placebo effect in reverse post corona vaccination symptoms
« Reply #1604 on: January 20, 2022, 09:59:19 AM »
https://nypost.com/2022/01/20/nocebo-effect-blamed-for-some-covid-vaccine-symptoms-study/

scare someone by telling them they will feel something - viola - they attribute every tiny thing to that.

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: placebo effect in reverse post corona vaccination symptoms
« Reply #1605 on: January 20, 2022, 10:12:58 AM »
https://nypost.com/2022/01/20/nocebo-effect-blamed-for-some-covid-vaccine-symptoms-study/

scare someone by telling them they will feel something - viola - they attribute every tiny thing to that.

Does that explain all the athletes suffering heart attacks?





ccp

  • Power User
  • ***
  • Posts: 18543
    • View Profile
Re: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc
« Reply #1610 on: January 22, 2022, 09:33:22 AM »
the use in countries that do not require prescription
is a problem with over use

in the US we are trying not to use
if not clearly necessary
this is why I will not prescribed "zpack " for corona and why it is no longer as effective when needed as it used to be

and no there is not much in the way of pharmaceutical company research for antibiotics
when there is it is for hospital use almost exclusively
  not enough profit for them apparently otherwise.

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile


G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: First it was bats, now it could be monkeys?
« Reply #1613 on: January 23, 2022, 08:00:39 AM »
https://www.insider.com/monkeys-escape-from-pennsylvania-truck-en-route-to-labratory-2022-1?fbclid=IwAR0q-YUjduq8xallHGZ0YentO9MEFFVrrHTkiq350_jDZIb-riRLhbnlmjw

"records show that monkeys in laboratories in the US have been found with tuberculosis, Chagas disease, cholera, and MRSA."

So have illegal aliens.



G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: Heads up! Ebola like virus in bats is spreading in China
« Reply #1616 on: January 23, 2022, 09:29:11 AM »



Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile
Re: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc
« Reply #1619 on: January 23, 2022, 12:39:48 PM »
Agreed, but in our pursuit of Truth, we consider a panoply of sincere and informed opinion.

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc
« Reply #1620 on: January 23, 2022, 01:17:58 PM »
Agreed, but in our pursuit of Truth, we consider a panoply of sincere and informed opinion.

Let's examine history as well.


https://www.cancer.org/cancer/cancer-causes/medical-treatments/des-exposure.html

Safe and effective.

Or not.




ccp

  • Power User
  • ***
  • Posts: 18543
    • View Profile
Macaques
« Reply #1624 on: January 25, 2022, 07:28:57 PM »
How many movies started like this?

https://en.wikipedia.org/wiki/Macaque

Could this be the start of the real Planet of the Apes:

https://en.wikipedia.org/wiki/Planet_of_the_Apes

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: Macaques
« Reply #1625 on: January 26, 2022, 10:18:00 PM »
Have you seen 28 Days Later? (Chimps in this one)

Then there is Outbreak:

https://www.youtube.com/watch?v=x0YiotiaGx4



How many movies started like this?

https://en.wikipedia.org/wiki/Macaque

Could this be the start of the real Planet of the Apes:

https://en.wikipedia.org/wiki/Planet_of_the_Apes

Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile
An early treatment option?
« Reply #1626 on: January 27, 2022, 06:41:06 AM »
Doctor’s Organization Has Treated Over 150,000 COVID-19 Patients With 99.99 Percent Survival (theepochtimes.com) (https://www.theepochtimes.com/doctors-organization-has-treated-over-150000-covid-19-patients-with-99-99-percent-survival_4236896.html?utm_source=Morningbrief&utm_campaign=mb-2022-01-27&utm_medium=email&est=foscp7tCJKkcIRy%2B5Dt3RslXEDLxYsghfxoj1oo7gmlhpcKlo2P0rQveBT2kVmHbnHll)


Doctor’s Organization Has Treated Over 150,000 COVID-19 Patients With 99.99 Percent Survival'Early Treatment Works, Period'By Meiling Lee January 26, 2022 Updated: January 27, 2022Print ()A doctor who has been offering free telehealth (https://www.theepochtimes.com/t-telehealth (https://www.theepochtimes.com/doctors-organization-has-treated-over-150000-covid-19-patients-with-99-99-percent-survival_4236896.html?utm_source=Morningbrief&utm_campaign=mb-2022-01-27&utm_medium=email&est=foscp7tCJKkcIRy%2B5Dt3RslXEDLxYsghfxoj1oo7gmlhpcKlo2P0rQveBT2kVmHbnHll#Print)) services to COVID-19 (https://www.theepochtimes.com/t-covid-19) patients during the pandemic says that early treatment for COVID-19 works, claiming that he has a 99.99 percent survival rate.
“We have a team of volunteer free doctors that donate their time to help treat these patients that come to us,” Dr. Ben Marble, the founder of myfreedoctor.com, an online medical consultation service, said at a roundtable discussion (https://rumble.com/vt62y6-covid-19-a-second-opinion.html) hosted by Sen. Ron Johnson (R-Wis.) on Jan. 24.
 
He added, “We deliver the early treatment protocols to them as early as we can, and we have a 99.99 percent survival rate. So, I believe myfreedoctor.com, (https://myfreedoctor.com/) the free volunteered doctors have settled the science on this—early treatment works, period!”
 
Marble was answering Johnson’s question about what people can do if they or their loved ones have COVID-19.
People can visit the website myfreedoctor.com, create an account, and fill out a patient intake form if the doctors are accepting new patients for that day. One of the doctors will then reach out in less than 24 hours. With a huge demand for their services, the physicians say they can only “accept a certain number of patients each day.”
 
Marble says that he and his small team of volunteer doctors prescribe [Dr. Peter] McCullough’s treatment protocol, which consists of hydroxychloroquine, ivermectin, monoclonal antibodies, prednisone, and other low-cost generic drugs. They also prescribe vitamins D and C, and zinc.
()Vitamin C bottles were on display in Miami, Florida on June 15, 2001. (Joe Raedle/Getty Images)McCullough, a cardiologist, and epidemiologist, along with several physicians put together an early treatment protocol to provide outpatient care for COVID-19 patients. Their paper was published in The American Journal of Medicine (https://img.theepochtimes.com/assets/uploads/2018/06/15/GettyImages-1321615-1200x800.jpg (https://img.theepochtimes.com/assets/uploads/2018/06/15/GettyImages-1321615-1200x800.jpg)) in August 2020.
Dr. Pierre Kory, a pulmonologist and the President at the Frontline COVID-19 Critical Care (FLCCC) Alliance, says that the public is not aware that there are doctors across the country who will provide telehealth and early treatment for COVID-19.
 
“On our website, we have a button, which says find a provider (https://covid19criticalcare.com/ivermectin-in-covid-19/covid-19-care-providers/). We’ve tried to collect as many telehealth providers that treat all states in the country,” Kory said.
 
“We are trying to let that message be known because that message is being suppressed that this disease is treatable,” he added.
Kory also claims that there is corruption at the federal level in suppressing early treatment with repurposed cheap drugs and their availability and that the Centers for Disease Control and Prevention (CDC) has been “captured by the pharmaceutical industry.”
“The corruption is because they don’t want you to use off-label, repurposed generic medicines. It does not provide profit to the system,” Kory said, adding that, “you know what’s going on in this country right now, is that the CDC has been captured by the pharmaceutical industry.”
 
“They sent out a memo in August of 2021, they sent out a similar memo back in the spring 2020, telling the nation’s physicians and pharmacists not to use generic medicines.”
 
The Epoch Times has reached out to the CDC for comment.
 
Early treatments were and continue to be discouraged by the CDC, whose guidance (https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html) since the beginning of the pandemic up until January 2022, only focused on people self-quarantining for 14 days, keeping hydrated, taking analgesics, and only seeking hospital care when they can’t breathe or turn blue. They also warned people to not take any medications not approved for COVID-19.
 
“People have been seriously harmed and even died after taking products not approved for use to treat or prevent COVID-19, even products approved or prescribed for other uses,” the CDC wrote on its potential treatments webpage (https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html).
 
The weblink provided for the alleged harmful product was related to a March 2020 health alert
(https://emergency.cdc.gov/han/2020/han00431.asp) warning of a serious health effect from ingesting non-pharmaceutical chloroquine phosphate used to clean fish tanks. This alert came after an Arizona man and his wife took the non-pharmaceutical drug in an attempt to self-medicate for COVID-19.
 
For the past two years, the U.S. Food and Drug Administration (FDA) has only authorized limited early outpatient treatments for COVID-19 that include monoclonal antibodies for high-risk patients and antiviral pills from Merck and Pfizer. However, the FDA on Jan. 24 announced (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron) it was limiting the use of Eli Lilly and Regeneron monoclonal antibodies only to patients “likely to have been infected with or exposed to a variant that is susceptible to these treatments.”
 
Johnson held the roundtable discussion to offer a different perspective on the response to the pandemic, including on “the current state of knowledge of early and hospital treatment, vaccine efficacy and safety, what went right, what went wrong, what should be done now, and what needs to be addressed long term.”
 
The discussion panel consisted of renowned health experts and scientists that included McCullough, Dr. Robert Malone, and Dr. Paul Marik.
 
According to a press release (https://www.ronjohnson.senate.gov/2022/1/rsvp-deadline-media-advisory), Johnson also invited over a dozen prominent figures involved in developing, promoting, and leading the pandemic response, including the CDC Director Dr. Rochelle Walensky and White House Coronavirus Response Coordinator Jeffrey Zients. All of the individuals declined to attend the forum.
(https://www.theepochtimes.com/author-meiling-lee)



ccp

  • Power User
  • ***
  • Posts: 18543
    • View Profile
Re: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc
« Reply #1629 on: January 27, 2022, 07:27:43 PM »
https://www.thegatewaypundit.com/2022/01/project-veritas-undercover-video-reveals-disadvantaged-people-taking-excessive-covid-vaccines-tax-funded-gift-card-incentive/

nurses should be prosecuted
and lose their licenses

losing their jobs is not enough for this

nothing will happen

everyone getting paid
to abuse the system ...... :x



Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile
« Last Edit: January 29, 2022, 09:02:53 AM by Crafty_Dog »

Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile
Supporting the next booster
« Reply #1633 on: January 30, 2022, 03:52:45 PM »


Predicting the next booster

Katelyn Jetelina
Jan 30   
Comment
Share
Si quiere leer la versión en español, pulse aquí.

The next big scientific discussion bubbling to the surface is the potential of another booster: Will SARS-CoV-2 continue to mutate to escape antibody protection? Do we need another booster? If so, what’s the next formula? For example, do we need an Omicron-specific vaccine? By the time an Omicron-specific vaccine is tested, we won’t have an Omicron wave anymore. So, is there still value in rolling it out?

All of the above are difficult questions to answer because they require predicting how this virus will mutate. Some scientific labs have started this work and the story they are finding is nothing short of fascinating.

Will SARS-CoV-2 continue to mutate to escape antibody protection?

While all viruses mutate in many ways, when talking about vaccines, we’re really only interested in how viruses change to escape immunity (called antigenic phenotype). With this lens, there are two sides of the viral evolution spectrum:

Flu: On one end, we have the flu. It mutates a lot to escape our immunity, and about every 2-5 years our immune systems need a new vaccine formula to fight the virus. The new vaccine formula is fairly predictable, because the virus mutates in a ladder-like pattern: there is one major lineage, and every few years, a new variant sweeps and the others go extinct. (See Panel A in the figure below for a depiction). Because of this ladder, we can predict fairly well—although we are sometimes off—where the virus may go to proactively create the next vaccine formula.


Volz et al (2013) Viral Phylodynamics. PLOS Computational Biology. Source Here.
Measles: On the other end of the spectrum is measles. While measles mutates, it does not mutate to escape immunity. It has a more balanced evolutionary tree (See panel B in the figure above). There is no immune pressure that constantly pushes one mutation to outcompete another. So there is no ladder-like pattern. And, thankfully, our vaccines from the mid-1960s still work today.

But the flu and measles are very different from coronaviruses. To understand how SARS-CoV-2 may change to escape immunity over time, we must look at other coronaviruses that have been circulating for decades.

CoV-229E

The Bloom lab explored how another coronavirus—called CoV-229E—evolved over time. This is one of the “common colds” that has been circulating since at least the 1960s, although we think much longer. CoV-229E is probably a good indicator of what’s to come with SARS-CoV-2 because the viruses look fairly similar. Also, and importantly, they are mutating largely in the same physical places. The purpose of this study was to assess how CoV-229E evolved over time, which may give us some insight into how SARS-CoV-2 will mutate over time. So what did they find?

CoV-229E mutated over time in a clear ladder-like pattern, just like the flu (see figure below).

Over time, mutations of CoV-229E eroded antibody protection. In other words, people that were only infected by CoV-229E in 1984 weren’t well protected today.

The rate of antibody erosion was highly variable across people.


Eguia et al (2021). A human coronavirus evolves antigenically to escape antibody immunity. PLOS Pathogens. Source Here
This tells us that we should expect a ladder-like evolution of SARS-CoV-2 through which we could predict the next variant.

However, much to our surprise, this hasn’t happened

SARS-CoV-2 has thrown us for a loop, as the mutations haven’t evolved in a ladder-like fashion. The next variant hasn’t been coming from the last: Omicron didn’t come from Delta, and Delta didn’t come from Alpha. The fact that SARS-CoV-2 has lacked a pattern of evolution like other coronaviruses or the flu is incredibly puzzling.


(Next Strain)
But (and this is a big but), we haven’t had a lot of time for this pattern to play out. It’s only been 2 years and other evolutionary trees, like CoV-229E, also had 2-year time frames in which there were no ladder-like changes.

We expect the ladder-like pattern to arise with SARS-CoV-2 eventually. But because it hasn’t yet, we don’t know which direction SARS-CoV-2 is heading. This makes proactively predicting the next booster formulas challenging and risky (from financial and logistic standpoints). This leads us to the next question…

Do we need another booster right now?

There are really two camps of thought right now:

There is not enough evidence that we need another booster. Boosters are working fantastically well against severe disease during the Omicron wave. For example, in the U.K., we see that even 4-6 months after inoculation, efficacy of a booster against hospitalization is 75-85% compared to 2-dose series, which has an efficacy of 30-35%. This is even the case with BA.2 (sister lineage of Omicron), where there is less immunity escape than BA.1. The same goes for those that received the original J&J with one booster. A study out of South Africa found that a second dose of J&J was 85% effective against hospitalization during a time when Omicron was circulating, compared with 63% after one dose. In addition, T-cells, our second line of defense that keeps us out of the hospital, are mutating but have much less evolutionary pressure than our first line of defense (antibody protection). So there’s also a chance the current vaccine series will continue to protect against severe disease for a while.


(UK Health Security Agency- Source Here)

(UK Health Security Agency- Source Here)
Roll-out another booster vaccine. On the other hand, Israel already rolled out a second booster (not Omicron specific formula) among those aged 60+ years. The Israel Health Ministry just released data showing a 3-fold decrease in severe disease among those with 60+ years with 2 boosters compared to 1 booster during the Omicron wave (see figure below). Looking forward, there’s a good chance the next variant will come from Omicron (although, because we lack a ladder-like pattern, we could be wrong). If Omicron had enough mutations for partial antibody escape, the next variant may have full immune escape. Boosting with an Omicron-specific formula would then significantly prepare us for what is to come.


(Israel Ministry of Health)
Bottom Line: As Yogi Berra said, “It's tough to make predictions, especially about the future.” And SARS-CoV-2 is making it even more difficult with its random evolutionary patterns. The booster discussion that will ensue among scientists in the coming months will be imperative to follow.

Love, YLE and Dr. Jesse Bloom

Dr. Jesse Bloom, PhD, is a viral evolutionary scientist and Professor at the Fred Hutch Cancer Research Center and Affiliate Professor, Genome Sciences & Microbiology at the University of Washington. He and his team led much of the research described above. He also graciously ensured that I captured this complex work accurately for the YLE audience.

“Your Local Epidemiologist (YLE)” is written by Dr. Katelyn Jetelina, MPH PhD—an epidemiologist, biostatistician, professor, researcher, wife, and mom of two little girls. During the day she has a research lab and teaches graduate-level courses, but at night she writes this newsletter. Her main goal is to “translate” the ever-evolving public health science so that people will be well equipped to make evidence-based decisions. This newsletter is free thanks to the generous support of fellow YLE community members. To support the effort, please subscribe here:

DougMacG

  • Power User
  • ***
  • Posts: 18294
    • View Profile
Covid age specific risk
« Reply #1634 on: January 31, 2022, 01:52:43 PM »
From Medical Fascism post:
Among COVID-19 exposed individuals,
people in their 70s have roughly twice the mortality of those in their 60s,
10 times the mortality of those in their 50s,
40 times that of those in their 40s,
100 times that of those in their 30s,
300 times that of those in their 20s,
and a mortality that is more than 3000 times higher than for children.
---------------------------------------------------

Are these ratios (approximately) true for omicron, same as other variants?

DougMacG

  • Power User
  • ***
  • Posts: 18294
    • View Profile
Virus theory, evolution
« Reply #1635 on: January 31, 2022, 04:39:42 PM »
Paraphrasing a very recently retired CEO of a major health insurer:

Virus is a living thing, wants to survive.  (Isn't that what all living things want to do?)
Virus is a parasite, dies without a living host.
Virus has mutated into way more variants than those we know of or named.
The ones that become most successful and dominant have these two qualities:
Maximum contagion while minimizing the fatality of the host.
Omicron did this.  Further dominant variants could (and should) be even less deadly.
The pandemic as we know ends this year.
« Last Edit: January 31, 2022, 05:51:16 PM by DougMacG »


ccp

  • Power User
  • ***
  • Posts: 18543
    • View Profile
Re: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc
« Reply #1637 on: February 01, 2022, 04:01:48 PM »
I am not clear where it states this is due to vaccine or corona infection

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: Epidemics: Bird Flu, TB, AIDs, Superbugs, Ebola, etc
« Reply #1638 on: February 01, 2022, 04:07:15 PM »
I am not clear where it states this is due to vaccine or corona infection

What else would it be?

Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile
New Ivermectin Study
« Reply #1639 on: February 02, 2022, 04:20:02 AM »
New Study on Ivermectin ‘Should Convince Any Naysayer’: Dr. Pierre Kory
By Zachary Stieber and Jan Jekielek February 1, 2022 Updated: February 1, 2022biggersmaller Print
A recently published study indicating the anti-parasitic ivermectin worked well as a prophylactic against the virus that causes COVID-19 should help sway critics of the drug, according to Dr. Pierre Kory, president of the Front Line COVID-19 Critical Care Alliance (FLCCC).

“That should convince any naysayer,” Kory told The Epoch Times’ “American Thought Leaders.” “What they found was astounding.”

The Brazilian city of Itajaí launched a program that gave ivermectin to any residents that wanted any. The period that was studied was from July 7, 2020, to December 2, 2020.

Researchers found that the program, which had over 100,000 residents participate, was linked to a 44 percent drop in COVID-19 cases.

Read More
Dr. Pierre Kory: The War on Hydroxychloroquine, Ivermectin, and Other Cheap Drugs to Treat COVID-19
Approximately 3.7 percent of ivermectin users contracted the illness during the trial period, compared to 6.6 percent of residents who didn’t take the drug.

The program was also associated with a statistically significant decrease in hospitalization and mortality.

The peer-reviewed study was published in Cureus on Jan. 15.

“Ivermectin MUST be considered as an option, particularly during outbreaks,” Dr. Flavio Cadegiani, one of the study’s authors and a founding member of FLCCC, told The Epoch Times in an email.

FLCCC focuses on early treatment of COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. The group has recommended ivermectin since early 2020.

Kory said the lack of reporting on the study despite it being peer-reviewed highlights how some scientific developments are ignored by many media outlets and scientists.

“You would think this would lead major headlines everywhere. And yet, nothing. And this is not new, this censorship of this highly effective science and evidence around repurposed drugs. The censoring of it, it’s not new, it’s just getting more and more absurd. And it has to stop,” he said.

Epoch Times Photo
A woman holds a box of ivermectin in Brasilia, Brazil in a file image. (Andressa Anholete/Getty Images)
Studies on ivermectin against COVID-19 have shown mixed results, with some being associated with no or little benefit and others suggesting a strong benefit. It’s been widely used in India and other countries as a preventative measure, but in the United States and much of Europe many official health care bodies recommend against its use or do not endorse it.

Ivermectin has been approved for certain uses by the Food and Drug Administration, but not for use against COVID-19. That means doctors can prescribe it off-label.

The National Institutes of Health’s COVID-19 treatment guidelines panel currently says that there is not enough evidence to advise either for or against using ivermectin to treat COVID-19. It does not address its potential use as a prophylactic.

While the new study was celebrated by some, others questioned the findings and pointed out that the conflicts of interest disclosures show both Cadegiani and another author have received funding from or contracted with Vitamedic, a company that manufactures ivermectin.

Gideon Meyerowitz-Katz, an Australian epidemiologist, for instance, called it “a fairly simple example of observational research that you’d do on routine medical data” but alleged the controls for confounding factors such as occupation and risk factors were “pretty inadequate given the purpose.”

Related Coverage
New Study on Ivermectin ‘Should Convince Any Naysayer’: Dr. Pierre KoryDr. Pierre Kory: The War on Hydroxychloroquine, Ivermectin, and Other Cheap Drugs to Treat COVID-19
Cadegiani said the criticism was unfounded, saying he wasn’t convinced before the study that ivermectin would work as a preventative medicine and that researchers controlled for “all relevant factors,” including comorbidities, age, sex, and race.

“Their inability to focus on the data provided by the study itself is … proof of the extreme high quality of the study,” the doctor said, adding later that “To us, this is the best observational study on COVID-19 to date, with a power almost equivalent to a huge randomized clinical trial.”

The researchers plan on publishing multiple additional papers regarding the program, including papers on the biochemical effects of ivermectin and the effectiveness of the drug in preventing hospitalization.



ccp

  • Power User
  • ***
  • Posts: 18543
    • View Profile
majority of myocarditis
« Reply #1641 on: February 02, 2022, 08:41:37 AM »
of the 1 out of roughly 150,000 vaccine recipients who get myocarditis will go home from hospital in short order on otc
motrin with total improvement
near 90%




G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
Re: majority of myocarditis
« Reply #1642 on: February 02, 2022, 09:58:24 AM »
of the 1 out of roughly 150,000 vaccine recipients who get myocarditis will go home from hospital in short order on otc
motrin with total improvement
near 90%

https://www.myocarditisfoundation.org/about-myocarditis/

In simple terms, myocarditis is a disease that causes inflammation of the heart muscle. This inflammation enlarges and weakens the heart, creates scar tissue and forces it to work harder to circulate blood and oxygen throughout the body.

While we often associate cardiovascular conditions with elderly populations, myocarditis can affect anyone, including young adults, children and infants. In fact, it most often affects otherwise healthy, young, athletic types with the high-risk population being those of ages from puberty through their early 30’s, affecting males twice as often as females. Myocarditis is the 3rd leading cause of Sudden Death in children and young adults.

As a layman, this strikes me as pretty serious.

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile

ccp

  • Power User
  • ***
  • Posts: 18543
    • View Profile
risk of myocarditis from corona infect. multiple times risk from corona vaccine
« Reply #1644 on: February 02, 2022, 01:30:49 PM »
https://www.cdc.gov/mmwr/volumes/70/wr/mm7035e5.htm

risk of myocarditis from corona infection 15.7 x normal
risk of myocarditis from vaccine 3.27 x normal in one analysis


"Since the introduction of mRNA COVID-19 vaccines in the United States in December 2020, an elevated risk for myocarditis among mRNA COVID-19 vaccine recipients has been observed, particularly among males aged 12–29 years, with 39–47 expected cases of myocarditis, pericarditis, and myopericarditis per million second mRNA COVID-19 vaccine doses administered (6). A recent study from Israel reported that mRNA COVID-19 vaccination was associated with an elevated risk for myocarditis (risk ratio = 3.24; 95% CI = 1.55–12.44); in the same study, a separate analysis showed that SARS-CoV-2 infection was a strong risk factor for myocarditis (risk ratio = 18.28, 95% CI = 3.95–25.12) (4). On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination clearly outweighed the risks for myocarditis after vaccination (6). The present study supports this recommendation by providing evidence of an elevated risk for myocarditis among persons of all ages with diagnosed COVID-19."

------

"Myocarditis is uncommon among patients with and without COVID-19; however, COVID-19 is a strong and significant risk factor for myocarditis, with risk varying by age group. The findings in this report underscore the importance of implementing evidence-based COVID-19 prevention strategies, including vaccination, to reduce the public health impact of COVID-19 and its associated complications."

G M

  • Power User
  • ***
  • Posts: 26643
    • View Profile
https://www.cdc.gov/mmwr/volumes/70/wr/mm7035e5.htm

risk of myocarditis from corona infection 15.7 x normal
risk of myocarditis from vaccine 3.27 x normal in one analysis


"Since the introduction of mRNA COVID-19 vaccines in the United States in December 2020, an elevated risk for myocarditis among mRNA COVID-19 vaccine recipients has been observed, particularly among males aged 12–29 years, with 39–47 expected cases of myocarditis, pericarditis, and myopericarditis per million second mRNA COVID-19 vaccine doses administered (6). A recent study from Israel reported that mRNA COVID-19 vaccination was associated with an elevated risk for myocarditis (risk ratio = 3.24; 95% CI = 1.55–12.44); in the same study, a separate analysis showed that SARS-CoV-2 infection was a strong risk factor for myocarditis (risk ratio = 18.28, 95% CI = 3.95–25.12) (4). On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination clearly outweighed the risks for myocarditis after vaccination (6). The present study supports this recommendation by providing evidence of an elevated risk for myocarditis among persons of all ages with diagnosed COVID-19."

------

"Myocarditis is uncommon among patients with and without COVID-19; however, COVID-19 is a strong and significant risk factor for myocarditis, with risk varying by age group. The findings in this report underscore the importance of implementing evidence-based COVID-19 prevention strategies, including vaccination, to reduce the public health impact of COVID-19 and its associated complications."

How many of those infected with Covid had taken at least one ClotShot?


Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile

Crafty_Dog

  • Administrator
  • Power User
  • *****
  • Posts: 69460
    • View Profile
Two new vaxxes
« Reply #1648 on: February 04, 2022, 09:54:26 AM »
second

   
Your Local (Infectious Disease) Epidemiologist

Two underdog but game changing vaccines: NVX-CoV2373 (Novavax) and CORBEVAX

Katelyn Jetelina
Feb 4   

Comment
Share
Si quiere leer la versión en español, pulse aquí.

One way (maybe the only way) we’re going to get out of this pandemic is to vaccinate a large portion of the global population. To the WHO, this means reaching 70% of the population by mid-2022, which is ~3 billion unvaccinated people with 6-9 billion doses before another variant of concern.


A diverse portfolio of vaccines that utilizes a number of different biotechnologies is of critical importance. While mRNA vaccines are innovative and effective, they pose logistical storage challenges to reach remote communities. The mRNA pharmaceutical companies are also not sharing their vaccine patent, which doesn’t allow others to manufacture. In addition, a diverse portfolio of vaccines frees up supply bottlenecks, provides options for those allergic to vaccines ingredients, and, among vaccines that use more traditional biotechnologies, will reduce vaccine hesitancy.

Two new vaccines have been added to our global repertoire: NVX-CoV2373 and CORBEVAX. These will be nothing short of game changers for the pandemic. Here is their story and how they work:

NVX-CoV2373

NVX-CoV2373 was created by Novavax, a small pharmaceutical company from Maryland. Before the pandemic they almost lost it all, but made a huge comeback after Operation Warp Speed took a chance on them. (I recommend reading their history over coffee; it’s fascinating). This will be their first vaccine to make it to the market.

Novavax is using a different vaccine biotechnology from other COVID19 vaccines. It contains the coronavirus spike protein combined with an immune-boosting compound from the soapbark tree. Once the immune system encounters the spike protein (which is harmless alone), the body produces antibodies against SARS-CoV-2 and thus protect from future infection.

This method has a much longer track record than the newer approaches, as it’s used for some flu and HPV vaccines. The exciting (and innovative) aspect of this vaccine is that Novavax found a way to make it in moth cells (rather than mammal cells). The moth cells become little factories that pump out coronavirus proteins. The scientists then extract and purify the spike proteins for vaccines. This allows Novavax to manufacture the vaccine much quicker than other vaccine types.

Phase III clinical trials (called PREVENT-19) were released in 2021 and results were published in the New England Journal of Medicine. NVX-CoV2373 had an efficacy of 100% against moderate-to-severe disease with the original variant and 90% efficacy overall. Which is nothing short of fantastic. Since, the vaccine has also been shown to be highly effective against other variants of concern, like Delta, Beta, and Omicron.

However, it’s taken months for Novavax to submit an EUA application to the FDA because they ran into some production issues. When a company applies to the FDA, they include data about the safety and effectiveness (which we all focus on), but they also submit data on manufacturing and production. And Novavax had a hard time passing production purity tests—the FDA requires vaccines to consistently pass a purity of 90% so contaminants don’t make the vaccine less effective or potentially cause some people to adversely react. Last October, Politico reported that Novavax was showing purity levels hovering around 70%.

This week Novavax announced they’re applying for an EUA in the United States—a signal that they refined their production to consistently pass purity tests for the FDA. Novavax has already been approved in several other countries, including India, South Africa, Australia and the E.U. On December 17, the WHO issued an emergency use listing (EUL) so Novavax could give a much-needed boost to COVAX—an international consortium of vaccine supply—to vaccinate more people in lower-income countries.

CORBEVAX

The second game changer vaccine is called CORBEVAX; in fact it’s been dubbed the “The World’s COVID-19 Vaccine.” This work was not led by a big (or small) pharmaceutical company but by two scientists at Texas Children’s Hospital and Baylor College of Medicine: Drs. Maria Elena Bottazzi and Peter Hotez. The two have been working together on coronavirus vaccines for the past two decades, including the development of a SARS vaccine in 2003. So when the pandemic hit, they were able to quickly pivot to COVID19. They were not funded through Operation Warp Speed. In fact, they had a very difficult time receiving funding from the government so they turned to philanthropic support, including from Tito’s Vodka.

CORBEVAX is also protein based, but uses a yeast fermentation method that’s been around for several decades and doesn’t use human or animal cells. In fact, this is the same biotechnology used to make the Hepatitis B vaccine, which millions of us already have.

CORBEVAX completed Phase III clinical trials in India, which involved more than 3,000 participants. The vaccine was found to be highly effective against the original virus, with a >90% vaccine effectiveness and 80% effective against Delta. The clinical trials showed it was also safe and well tolerated, as it had 50% fewer adverse events than other vaccines. As NPR reported, one drawback to this biotechnology is that it can't be modified as quickly as mRNA vaccines for new variants.

Because this vaccine biotechnology has been around for a long time and because Drs. Hotez and Bottazzi made the intellectual property available to everybody, vaccine producers all around the world can make it. In fact, CORBEVAX is already licensed to four vaccine producers: Biological E in India, Biopharma in Indonesia, Septa in Bangladesh, and ImmunityBio in South Africa and Botswana. On December 28, it was authorized for emergency use in India. And, two days ago, Drs. Hotez and Bottazzi were nominated for the Nobel Peace Price.

Bottom line: The underdogs are pulling through! And we should all be cheering as these add diversity to our vaccine portfolio, which will get us one step (or more like leaps) closer to ending the pandemic.

Love, YLE

“Your Local Epidemiologist (YLE)” is written by Dr. Katelyn Jetelina, MPH PhD—an epidemiologist, biostatistician, professor, researcher, wife, and mom of two little girls. During the day she has a research lab and teaches graduate-level courses, but at night she writes this newsletter. Her main goal is to “translate” the ever-evolving public health science so that people will be well equipped to make evidence-based decisions. This newsletter is free thanks to the generous support of fellow YLE community members. To support the effort, please subscribe here: